Shopping Cart
Remove All
Your shopping cart is currently empty
Ibritumomab tiuxetan (IDEC-129) is an antibody targeting CD20, conjugated to a radioactive isotope via a chelating agent Tiuxetan, and can be used in radioimmunotherapy.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $195 | Inquiry | Inquiry | |
| 5 mg | $483 | Inquiry | Inquiry | |
| 10 mg | $692 | Inquiry | Inquiry | |
| 25 mg | $1,080 | Inquiry | Inquiry | |
| 50 mg | $1,490 | Inquiry | Inquiry | |
| 100 mg | $1,970 | Inquiry | Inquiry |
| Description | Ibritumomab tiuxetan (IDEC-129) is an antibody targeting CD20, conjugated to a radioactive isotope via a chelating agent Tiuxetan, and can be used in radioimmunotherapy. |
| In vitro | Ibritumomab tiuxetan is an anti-CD-20 mouse monoclonal antibody linked to the radioisotope 90-yttrium (90Y) by the chelating agent tiuxetan. [1] |
| Synonyms | IDEC-129, IDEC129, BAY86-5128, BAY865128 |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Cas No. | 206181-63-7 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.